Broide, David H.Stachnick, GregCastaneda, DiegoNayar, JyothiMiller, MarinaCho, Jae YounRoman, MarkZubeldia Ortuño, José ManuelHyashi, TomokoRaz, Eyal2024-01-292024-01-292001-05-01Broide DH, Stachnick G, Castaneda D, Nayar J, Miller M, Cho JY, Roman M, Zubeldia J, Hayashi T, Raz E. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. Actions Share Page navigation Title & authors Erratum in Abstract Similar articles Cited by References Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources J Clin Immunol . 2001 May;21(3):175-82.0271-914210.1023/a:1011078930363https://hdl.handle.net/20.500.14352/95765This study investigated whether immunostimulatory DNA sequences (ISS) induce a transient or sustained inhibition of Th2 responses to inhaled antigen. We sensitized mice with subcutaneous injections to develop a Th2 response to ovalbumin (ova) and then administered a dose of ISS prior to ova inhalation challenge. Mice were then rechallenged with ova by inhalation a second time at varying time points after the first ova inhalation (1 to 8 weeks later) to determine whether the ISS dose administered prior to the first ova inhalation protected against a subsequent second ova inhalation challenge. A single dose of ISS inhibited the Th2 response to the first inhalation of ova antigen, as well as 4 weeks later to the second inhalation of ova. However, ISS did not inhibit a Th2 response to the second inhalation of ova 8 weeks later. The reversible inhibition of Th2 responses at 8 weeks suggests the need for repeated ISS administration at monthly intervals.engjournal articlehttps://link.springer.com/article/10.1023/A:1011078930363https://pubmed.ncbi.nlm.nih.gov/11403224/restricted access616.248IL-5eosinophilsinterferon gammaasthmaCpG motifCiencias Biomédicas32 Ciencias Médicas